XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.3
DISCONTINUED OPERATIONS - Major Classes of Line Items in Income From Discontinued Operations (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Other operating income, net $ (5) $ 0 $ (9) $ (14)
Operating income 155 179 449 403
Interest expense, net 87 127 251 367
Other (income) expense, net (1) (12) (34) 15
Income from discontinued operations, net of tax 83 2,474 (290) 2,455
Net income attributable to noncontrolling interests included in discontinued operations 4 3 9 6
Income (loss) from discontinued operations attributable to Baxter stockholders 79 2,471 (299) 2,449
Discontinued Operations, Disposed of by Sale        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Net sales 1,155 1,300 3,375 3,763
Cost of sales 731 1,129 2,125 3,057
Gross margin 424 171 1,250 706
Selling, general and administrative expenses 278 273 874 735
Research and development expenses 41 34 140 106
Goodwill impairment     430 0
Other operating income, net (1) 0 (1) 0
Operating income 106 (136) (193) (135)
Interest expense, net 1 1 0 2
Other (income) expense, net (8) 7 (2) 20
Income (loss) from discontinued operations before gain on disposition and income taxes 113 (144) (191) (157)
Gain on disposition 0 2,890 0 2,890
Income tax expense (benefit) 30 272 99 278
Income from discontinued operations, net of tax 83 2,474 (290) 2,455
Net income attributable to noncontrolling interests included in discontinued operations 4 3 9 6
Income (loss) from discontinued operations attributable to Baxter stockholders 79 2,471 (299) 2,449
Discontinued Operations, Disposed of by Sale | Kidney Care        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Net sales 1,155 1,109 3,375 3,294
Cost of sales 731 1,048 2,125 2,841
Gross margin 424 61 1,250 453
Selling, general and administrative expenses 278 258 874 691
Research and development expenses 41 33 140 104
Goodwill impairment     430 0
Other operating income, net (1) 0 (1) 0
Operating income 106 (230) (193) (342)
Interest expense, net 1 1 0 2
Other (income) expense, net (8) 5 (2) 18
Income (loss) from discontinued operations before gain on disposition and income taxes 113 (236) (191) (362)
Gain on disposition 0 0 0 0
Income tax expense (benefit) 30 (250) 99 (258)
Income from discontinued operations, net of tax 83 14 (290) (104)
Net income attributable to noncontrolling interests included in discontinued operations 4 3 9 6
Income (loss) from discontinued operations attributable to Baxter stockholders 79 11 (299) (110)
Discontinued Operations, Disposed of by Sale | BioPharma Solutions        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Net sales 0 191 0 469
Cost of sales 0 81 0 216
Gross margin 0 110 0 253
Selling, general and administrative expenses 0 15 0 44
Research and development expenses 0 1 0 2
Goodwill impairment     0 0
Other operating income, net 0 0 0 0
Operating income 0 94 0 207
Interest expense, net 0 0 0 0
Other (income) expense, net 0 2 0 2
Income (loss) from discontinued operations before gain on disposition and income taxes 0 92 0 205
Gain on disposition 0 2,890 0 2,890
Income tax expense (benefit) 0 522 0 536
Income from discontinued operations, net of tax 0 2,460 0 2,559
Net income attributable to noncontrolling interests included in discontinued operations 0 0 0 0
Income (loss) from discontinued operations attributable to Baxter stockholders $ 0 $ 2,460 $ 0 $ 2,559